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Objectives: By reducing the frequency of oral bisphosphonate dosing, and potentially improving tolerability, a once-monthly 
regimen may enhance therapeutic adherence, which is currently suboptimal with daily and weekly oral bisphosphonates. The 
MOBILE study was performed to formally compare the efficacy and safety of once-monthly oral ibandronate with an established 
daily oral ibandronate regimen after 1-year of treatment. Here we report the confirmatory analysis of the 2-year results of this study. 
Methods: MOBILE, a randomised, double-blind, phase III trial, compared the efficacy and safety of three once-monthly oral 
ibandronate regimens (50+50mg, 100mg and 150mg) with an efficacious (3-year vertebral fracture risk reduction: 62%) and well 
tolerated daily oral ibandronate regimen (2.5mg) (1). Participants were women (aged 55-80 years; = 5 years since menopause) with 
postmenopausal osteoporosis (PMO) (lumbar spine BMD T-score <-2.5 and = -5). All participants received daily calcium (500mg) 
and vitamin D (400IU). A non-inferiority analysis was used to compare increases from baseline in lumbar spine BMD between the 
once-monthly and daily regimens. 
Results: A total of 1,609 women were randomized. At 2 years, as after 1 year, all once-monthly regimens were proven at least 
as effective as the daily regimen in producing substantial increases above baseline in lumbar spine (L2-L4) BMD: 5.3%, 5.6% and 
6.6% in the 50+50mg, 100mg and 150mg once-monthly groups, respectively, compared with 5.0% in the daily group. The 150mg 
regimen continued to be superior to daily ibandronate (p<0.001). Hip BMD at all regions (total hip, femoral neck and trochanter) 
increased substantially in all treatment groups, being most pronounced in the 150mg group (Table). The sizeable decreases in 
sCTX observed in all treatment arms after 3 months were maintained throughout the second year, with reductions of 56.1%, 60.5% 
and 67.7% in the 50+50mg, 100mg and 150mg once-monthly groups, respectively, compared with 61.5% in the daily arm. The 
majority of participants responded positively to oral ibandronate therapy with BMD increases and bone resorption decreases: 71-
94% achieved increases in lumbar spine and/or total hip BMD above baseline and 61-79% achieved a reduction in sCTX of at least 
50% from baseline. In the 150mg once-monthly, group response rates for all BMD measures were consistently over 80%. After the 
2-year treatment period, the good tolerability observed after 1-year was confirmed for all of the once-monthly treatment regimens, 
with a similar incidence of adverse events to daily administration. 
 
Mean change (%) from baseline in proximal femur BMD at 2 years.
2.5mg daily 50/50mg monthly 100mg monthly 150mg monthly
(n=292) (n=291) (n=277) (n=289)
Total hip 2.5 2.8 3.5 4.2
Femoral neck 1.9 2.1 2.6 3.1




Conclusion: Once-monthly oral ibandronate is highly effective and well tolerated in the treatment of PMO. The benefits of the 
consistently greater increases in BMD and sCTX suppression reported for the 150mg once-monthly arm versus the 100mg and 
daily regimens at 1-year were maintained throughout the second year of treatment. Therefore, once-monthly ibandronate may 
provide a useful alternative to daily and weekly bisphosphonates. Additionally, this new, less-frequently administered regimen may 
lead to improved adherence and therefore treatment outcomes. 
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